Ensysce Biosciences Advances PF614 Phase 3 Trial with FDA Manufacturing Approval and Extended Patent Protection
Key Insights
Ensysce Biosciences initiated enrollment for its pivotal PF614-301 Phase 3 trial in December 2025, evaluating the abuse-resistant oxycodone analgesic for post-surgical pain management.
The FDA provided positive feedback on Ensysce's commercial manufacturing strategy for PF614, agreeing with proposed regulatory starting materials and specifications to enable commercial-scale production.
The company secured up to $20 million in funding through November 2025 and extended MPAR (search)® patent protection through 2042, strengthening its intellectual property portfolio.
Ensysce Biosciences has achieved significant regulatory and clinical milestones for its lead abuse-resistant opioid candidate PF614, with Phase 3 enrollment underway and FDA alignment on commercial manufacturing strategy positioning the company for potential market entry.
Phase 3 Trial Enrollment Initiated
In December 2025, Ensysce initiated subject enrollment for its pivotal PF614-301 Phase 3 clinical trial at two clinical sites, with additional sites expected to follow. The multicenter, randomized, double-blind, placebo- and active-controlled study is evaluating PF614's efficacy and safety for treating moderate to severe pain (search) following abdominoplasty.
PF614 is an extended-release oxycodone analgesic incorporating Ensysce's proprietary TAAP (search)™ (Trypsin-Activated Abuse Protection) technology. The drug is designed to activate only when swallowed and exposed to trypsin in the small intestine, rendering it highly resistant to tampering and reducing abuse potential through non-oral routes of administration.
The company partnered with Rho, Inc., a leading contract research organization with extensive experience in central nervous system and pain studies, to ensure rigorous trial execution. Ensysce anticipates providing enrollment and progress updates during the first half of 2026.
FDA Manufacturing Alignment Achieved
In November 2025, Ensysce received constructive written feedback from the FDA regarding its commercial manufacturing strategy for PF614. The Agency agreed with all of the company's proposed regulatory starting materials, drug substance specifications, and overall chemistry, manufacturing and controls approach.
"We are extremely pleased with the FDA's feedback, which validates our approach and enables us to accelerate PF614's path to market," stated Dr. Jeff Millard, Chief Operating Officer of Ensysce. "This milestone brings us closer to providing safer pain relief options for patients in need."
The FDA alignment provides a clear and direct path to commercial-scale manufacturing. Ensysce has initiated drug substance manufacturing activities with Purisys, LLC (search), a subsidiary of Noramco, and is working with drug product manufacturing partner Galephar (search) to support NDA registration readiness.
Overdose Protection Program Advances
Ensysce's second clinical candidate, PF614-MPAR, combines PF614 with the company's proprietary MPAR (search)® overdose protection technology. The drug is engineered to "switch off" opioid release in an overdose scenario and continues advancing under FDA Breakthrough Therapy designation.
The program received strong support from the National Institute on Drug Abuse (NIDA (search)), with Ensysce receiving the second $5 million installment of its multi-year NIDA grant in June 2025, bringing total non-dilutive funding to over $25 million. The current grant extends through 2027, with a third $5 million installment expected in June 2026.
Key developments included encouraging FDA feedback regarding overdose protection labeling and support for a streamlined 505(b)(2) registration pathway, along with collaborative work on a scientific whitepaper articulating the rationale behind overdose protection labeling.
Intellectual Property and Financial Strengthening
In November 2025, the U.S. Patent and Trademark Office issued a Notice of Allowance for a new MPAR (search)® patent, extending intellectual property protection through 2042. The patent includes both composition-of-matter and method-of-use claims, representing the strongest form of patent protection available.
The company completed a $4 million convertible preferred financing in November 2025, providing access to up to $20 million in total capital over 24 months. The financing structure includes a fixed conversion price of $2.50 per share and 50% warrant coverage, supporting execution of the PF614 Phase 3 program and extending operating runway.
Expanding Pipeline Development
Ensysce identified PF9001 as its lead opioid use disorder (search) candidate, leveraging both TAAP (search)™ and MPAR (search)® technologies. The program is designed to limit abuse, reduce cardiovascular risk, and incorporate built-in overdose protection, supported by a multi-year grant through the HEAL program with encouragement from NIDA (search).
"The progress achieved in 2025 has laid a strong foundation for the year ahead," said Dr. Lynn Kirkpatrick, Chief Executive Officer. "We remain committed to advancing the next generation of powerful analgesics that address the severest of pain while incorporating safeguards aligned with modern public health priorities."